Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
Hajiev S, Allara E, Motedayеn Aval L, Arizumi T, Bettinger D, Pirisi M, Rimassa L, Pressiani T, Personeni N, Giordano L, Kudo M, Thimme R, Park JW, Taddei TH, Kaplan DE, Ramaswami R, Pinato DJ, Sharma R. Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study. British Journal Of Cancer 2020, 124: 407-413. PMID: 33071284, PMCID: PMC7852559, DOI: 10.1038/s41416-020-01116-9.Peer-Reviewed Original ResearchConceptsOverall survivalHepatocellular carcinomaCohort studySorafenib-related toxicityInternational cohort studyMedian overall survivalMulticentre cohort studyLow-dose therapyCommon prognostic factorsSimilar overall incidenceDoses of sorafenibImpact of ageConclusionsClinical outcomesSorafenib 800Sorafenib dosingElderly patientsOlder patientsPrognostic factorsOverall incidenceClinical efficacyLiver functionLarge tumorsMultivariable modelGrade 2PatientsAn international cohort study investigating the impact of age on clinical outcome in patients with hepatocellular carcinoma treated with sorafenib.
Sharma R, Hajiev S, Aval L, Bettinger D, Arizumi T, Pirisi M, Rimassa L, Personeni N, Pressiani T, Giordano L, Kudo M, Thimme R, Park J, Taddei T, Kaplan D, Ramaswami R, Pinato D, Allara E. An international cohort study investigating the impact of age on clinical outcome in patients with hepatocellular carcinoma treated with sorafenib. Journal Of Clinical Oncology 2020, 38: 12049-12049. DOI: 10.1200/jco.2020.38.15_suppl.12049.Peer-Reviewed Original ResearchOverall survivalStarting doseHepatocellular carcinomaAdvanced-stage hepatocellular carcinomaLower starting doseSorafenib-related toxicityMedian overall survivalMulticentre cohort studyPortal vein thrombosisTerms of OSLow-dose therapyDose of sorafenibRates of toxicitySorafenib dosingSorafenib toxicityChild-PughDose therapyCohort studyElderly patientsOlder patientsVein thrombosisClinical efficacySimilar incidenceSpecialist centresLarge tumors